JFIFFF bPhotoshop 3.08BIM COVID-19 2SOI Social Issues  infectionpandemicmedicine coronavirus machinery facilitiesCOVID-19 treatmentindustry   medication equipment enterprise  disease medical care pharmaceutics720201006<103950+0>?AFotoStation 8.0 WinPStanislav KrasilnikovZSaransk_MordoviaeRussiaiNProduction of coronavirus drug Areplivir at Biokhimik plant in Saransk, Russian /sxSARANSK, RUSSIA - OCTOBER 6, 2020: A worker oversees the process of granulation of pills and forming their cores at the Biokhimik pharmaceutical plant where the Areplivir drug developed by Promomed for COVID-19 treatment is produced, in Saransk, capital of Mordovia. Founded in 1959, Biokhimic specialises in manufacturing different groups of antibiotics, including penicillins, cephalosporins, carbapenems, aminoglycosides. Areplivir was registered by the Russian Healthcare Ministry on June 23, 2020, being the second Russian-made drug based on favipiravir, a synthetic medication earlier used to treat rare viral infections, including Ebola virus, along with complicated influenza diseases. Stanislav Krasilnikov/TASS . . "" ( ""), COVID-19 "". "" 1959 . , , , , . "" 23 2020 , , , . /zCP_1251 0:0:0:003587U 6e3dd15f42dc4cfeae9d01a86872829d20201006# 160051+0300y20201006-145342-8633_SK1_3587-241862933Ut2020 TASS, all rights reservedK(dRUSgF%&*-/2\v M06.10.2020 16:04:10 Text Saved by Orphea Studio (c)1997-2014 Algoba Systems.M06.10.2020 16:19:52 Text Saved by Orphea Studio (c)1997-2014 Algoba Systems.M06.10.2020 16:31:46 Text Saved by Orphea Studio (c)1997-2014 Algoba Systems.M06.10.2020 16:43:07 Text Saved by Orphea Studio (c)1997-2014 Algoba Systems.M06.10.2020 17:33:51 Text Saved by Orphea Studio (c)1997-2014 Algoba Systems.M06.10.2020 18:19:39 Text Saved by Orphea Studio (c)1997-2014 Algoba Systems.8BIMEE8BIM%D_o 8BIM )ExifMM*  (102;,i0Россия. Саранск. Процесс гранулирования таблеткой массы и изготовление ядра таблетки на заводе АО "Биохимик" (входит в группу компаний "Промомед"), где производится препарат от новой коронавирусной инфекции COVID-19 "Арепливир". Завод медицинским препаратов "Биохимик" основан в 1959 году для производства антибиотиков. На предприятии функционируют пять цехов, оснащенных высокотехнологичным оборудованием, специализирующимся на выпуске таблеток и капсул, мазей и гелей, растворов в ампулах. "Арепливир" зарегистрирован Минздравом РФ 23 июня 2020 года и стал вторым CanonCanon EOS-1D X Mark IIFFAdobe Photoshop Lightroom Classic 9.1 (Windows)2020:10:06 15:02:59Красильников Станислав#ڂ"'024850" *2 :B  J5555 R  RZ1 b2p45  2020:10:06 10:39:502020:10:06 10:39:50+03:00+03:00+03:00ΘB@-TB@2083012000053FEF24-70mm f/2.8L II USM4555007527 (!FFJFIFFFC  !"$"$C }!1AQa"q2#BR$3br %&'()*456789:CDEFGHIJSTUVWXYZcdefghijstuvwxyz w!1AQaq"2B #3Rbr $4%&'()*56789:CDEFGHIJSTUVWXYZcdefghijstuvwxyz ?HXpkC $Mu8r+XNۊY>>LifQlT!*K4Po$9$ѵS>tp: :2+!1ysPEf*e;$Z+EkGq"_4-ҭVfVZem^EZ^ĸeHtmH kNQ{gIuSI0:;pq\Xp2(GORiW<6ɢQ#6vU r zWg,]0xZ\Ŗ9߆ n?ͭ6K.~yY$}ob6 v/ڜ`c4ֵLDZ`qކRq]5ꕑO fߺdЁ=qNQ6tBqJrvC$mQIȥrPxfXAW5%ؒ ͒yNhЊH]4ԉq15 [ȈP5j23S?vhVc _jV|&p0JY5tq鬳Jx㨬F&}iq,ƤMV1.WǯkЙ!zrTLIXagh-a>J©vy^|P}9742Hrj fhXc%q֎bNoq`r҉;rqs)ᕫ'&(#\)>CDPN G1j6*'|c r3 hCz9XXga#MԱ)*ǚ+ 3}zmj:$WϘQU5)$DGͽ@{`H)8CY,F'k{ܣ:kY'a|lU7WjQLglOQj4wvY9juZzLXesx.C|{*Siu+1,qGA[V9YkMW 1n] ,tvI m霊vn .* )1d6:[.L֦Z;9cAXT;:=2]=teh3Cc2*Xљ el8+62k}^O $>qS-PeMԟgcv>{CMU{H9WBٯHbxZAuyY?tMF|U: +n}.ụ̄k",b!X+7Q`MF+'4W)B[Tc#ԽJs"t u!C!U݃FO5<<Mu Zo]%|ҟ3;-k΃͍S\f'[)GK,d2?DWPgminh~Hd N>>XeȲ1RdVVj޵#9 .Bfj=KФv^/uE,xxխ89lD棹xvHg1۽;CU(8J}C"wJEयc R+#CkMVB'Xqfm QnS9heMݪAu6FqEg(YӺ1;8VznMhZItZdYDJ9N7rM\zX[K|GKo'gCk)#)]Ǎ'zM"{_~lz$35 ֩Sl1D1B0M_1ح# hKi7z, 11+Re)^}u+jR%$#gD )J\UMUWjxo4EpaT HeP2i*Þ<ñEeVrxPN3P.ǡɦKms( cy6?HD1hZCopH*Ob0zQ4K;Tm E1>y-ۿCJV$DB |XlUSjmqbVn5'KH'bmҮmm7hYI֒ ۟)8銸MI55mJ_voq!o:XwX~SPF< +-;>8"ĊI ֢\r4RtW~?GɆ$?_Zj9Fj˽7U^ۓgCGֳU5MgZ;y]`մӥ"4$>M4Nf)۴,zXimaD` ;R\X|5o9G4SV,(H2+ˋݞ˅;-#&lRZUq9\T$kAGf6X`p1`CnDRIp#8V|'T]-,fhfB;s+0Mue " y#l]Q\cr\c=[WkE|X+z.:Nt#zCk*6BvzTㆩ $RsOSGA'Fi!)e:V(Fim;:n1Bde{Vu1q.J"I^!_6fBȒ(,7NQWNfLlgLYΒF2SEhYWV2 i%?,юx9^:^RяW۷Ĉ\ j=7'[%y/l9zmKFxo$Tp_U݅b=:g7NI]*iԞRSs8bO0tU*: PL<_,mk!s#޺UDltm*bL ,VؾB:B{V+I4ZdnnMSt]ZO(99l:Hola9}7sOF{mk;i)7F=qG}3v 42{ 铲3J3,ViK%I/~^tyHg6Z{Ѧ;sϥUR$fxr IӴ9nVNIc}Q>%C%֜rc_P}bim.\3JrI"wOͩ l֑8z7gGpK/5Ei:mq 6i3m."ߥmCE?X xBCG9 ;;{\LUǨ[ŵ.b*mФή KD'a~T[RZ#EB:nOr*h6+X-ݗKk&V'/^sU'hѻ\(--;+ cUWsq\L\/ҵHbRb`}~C5H+7m.@`sC#h]WwIּS zDm=ĭ +$p9Q֮5+6}\ҍ|?kӆWfd"BF]p sVk>r7jgOI鎝hv[Ы^[xnO_쵸ZI'ݽ|{{/K2751un%' f+h\Aq4v620 k*J֝9kbeg\EYSGq\Ğk I\'iQ t1@g\2{sOC[BDJ7, CnYG_H&UIg2M (,dʰ)sE}rSjVFi|64tfα;KKLyaR3sAM uXP`Qǭ'I^Dlt>)hYA?gap8>浥2z,liZY8'=Su9s9FC\ع!_&\q[ʥ6d(ΓIVԢS#g~윮d$:w6k[Q?e #WXxг$$_ۚb*+שZ[Gk-pHYF6ۻS3iZ}m㫅a h:o%MomKunk+ n1F7x-柦OȰ u22vK?sؚڻj7ٓM]>2_ww}ſ47CcA^<ɨ+|Uc`ռebM)d8$+A ҭ(xAwvʾmNIuI?Qs+OIIqwj&lA"eʲVkI-fV3f/.w< M"v2.:ǯ DW8qчZɡZմ# u8;h6$\@5|=_tʯE4zy%ٴI\e-t,n[i Xr+;ri8B GW{3ZgC rLe|c$.79g޺ZPZ29CxaԐG2g$\JeKV1L43މG茔TxkZMƕu qJJg7M!&Y|V?mW&m?[]Fѣ;$rc9#qQqЛp[˧KwK{(z߽Ejiɡ|$8āSv#McMjxi$gFI++qk[ YKATעq½XdT5a` `z,fsArE&;sL`M@\SPl2btb֗-'"MҵK_":HI065ny5Mh4mkP>k&QYC<{X= TIdWg]; $ K#,WއFs_5[}CE2dI&=hLAY#5"*^A d4%WԲ*hG1]6щ#EW2Cb[.@Ri2ΆXxwz2ޯ+"zdx{Ħ$PބkhՕPK<:$ZAKk_;a>PW#+#fO 2kĠ@#-Lu5wld+h2A7=pi44+ q֡G#sV%rs@6(r9iN $(9r cVȠW$wW$>]@ 14 0}Erk{Qr= I; q^JѨo l2> H +7N16g_k7:|3I(H)͵c;Ykmj#RKP&Ere3ue)9w)C7)4 hH. XICC_PROFILE HLinomntrRGB XYZ  1acspMSFTIEC sRGB-HP cprtP3desclwtptbkptrXYZgXYZ,bXYZ@dmndTpdmddvuedLview$lumimeas $tech0 rTRC< gTRC< bTRC< textCopyright (c) 1998 Hewlett-Packard CompanydescsRGB IEC61966-2.1sRGB IEC61966-2.1XYZ QXYZ XYZ o8XYZ bXYZ $descIEC http://www.iec.chIEC http://www.iec.chdesc.IEC 61966-2.1 Default RGB colour space - sRGB.IEC 61966-2.1 Default RGB colour space - sRGBdesc,Reference Viewing Condition in IEC61966-2.1,Reference Viewing Condition in IEC61966-2.1view_. \XYZ L VPWmeassig CRT curv #(-27;@EJOTY^chmrw| %+28>ELRY`gnu| &/8AKT]gqz !-8COZfr~ -;HUcq~ +:IXgw'7HYj{+=Oat 2FZn  % : O d y  ' = T j " 9 Q i  * C \ u & @ Z t .Id %A^z &Ca~1Om&Ed#Cc'Ij4Vx&IlAe@e Ek*Qw;c*R{Gp@j>i  A l !!H!u!!!"'"U"""# #8#f###$$M$|$$% %8%h%%%&'&W&&&''I'z''( (?(q(())8)k))**5*h**++6+i++,,9,n,,- -A-v--..L.../$/Z///050l0011J1112*2c223 3F3334+4e4455M555676r667$7`7788P8899B999:6:t::;-;k;;<' >`>>?!?a??@#@d@@A)AjAAB0BrBBC:C}CDDGDDEEUEEF"FgFFG5G{GHHKHHIIcIIJ7J}JK KSKKL*LrLMMJMMN%NnNOOIOOP'PqPQQPQQR1R|RSS_SSTBTTU(UuUVV\VVWDWWX/X}XYYiYZZVZZ[E[[\5\\]']x]^^l^__a_``W``aOaabIbbcCccd@dde=eef=ffg=ggh?hhiCiijHjjkOkklWlmm`mnnknooxop+ppq:qqrKrss]sttptu(uuv>vvwVwxxnxy*yyzFz{{c{|!||}A}~~b~#G k͂0WGrׇ;iΉ3dʋ0cʍ1fΏ6n֑?zM _ɖ4 uL$h՛BdҞ@iءG&vVǥ8nRĩ7u\ЭD-u`ֲK³8%yhYѹJº;.! zpg_XQKFAǿ=ȼ:ɹ8ʷ6˶5̵5͵6ζ7ϸ9к<Ѿ?DINU\dlvۀ܊ݖޢ)߯6DScs 2F[p(@Xr4Pm8Ww)Km"http://ns.adobe.com/xap/1.0/xpacket begin='' id='W5M0MpCehiHzreSzNTczkc9d'?> RUS 2 Производство препарата от коронавируса "Арепливир" на заводе "Биохимик" в Саранске МП 20201006 Саранск Республика Мордовия Россия Станислав Красильников/ТАСС ТАСС SOI Общество Social Issues Orphea Studio 4 SARANSK, RUSSIA - OCTOBER 6, 2020: A worker oversees the process of granulation of pills and forming their cores at the Biokhimik pharmaceutical plant where the Areplivir drug developed by Promomed for COVID-19 treatment is produced, in Saransk, capital of Mordovia. Founded in 1959, Biokhimic specialises in manufacturing different groups of antibiotics, including penicillins, cephalosporins, carbapenems, aminoglycosides. Areplivir was registered by the Russian Healthcare Ministry on June 23, 2020, being the second Russian-made drug based on favipiravir, a synthetic medication earlier used to treat rare viral infections, including Ebola virus, along with complicated influenza diseases. Stanislav Krasilnikov/TASS Россия. Саранск. Процесс гранулирования таблетной массы и изготовление ядра таблетки на заводе АО "Биохимик" (входит в группу компаний "Промомед"), где производится препарат от новой коронавирусной инфекции COVID-19 "Арепливир". Завод медицинским препаратов "Биохимик" основан в 1959 году для производства антибиотиков. На предприятии функционируют пять цехов, оснащенных высокотехнологичным оборудованием, специализирующимся на выпуске таблеток и капсул, мазей и гелей, растворов в ампулах. "Арепливир" зарегистрирован Минздравом РФ 23 июня 2020 года и стал вторым в России препаратом на основе действующего вещества фавипиравир, которое раньше применялось в лечении редких форм вирусных инфекций, в том числе лихорадки Эбола, а также сложных форм гриппа. Станислав Красильников/ТАСС SARANSK, RUSSIA - OCTOBER 6, 2020: A worker oversees the process of granulation of pills and forming their cores at the Biokhimik pharmaceutical plant where the Areplivir drug developed by Promomed for COVID-19 treatment is produced, in Saransk, capital of Mordovia. Founded in 1959, Biokhimic specialises in manufacturing different groups of antibiotics, including penicillins, cephalosporins, carbapenems, aminoglycosides. Areplivir was registered by the Russian Healthcare Ministry on June 23, 2020, being the second Russian-made drug based on favipiravir, a synthetic medication earlier used to treat rare viral infections, including Ebola virus, along with complicated influenza diseases. Stanislav Krasilnikov/TASS Россия. Саранск. Процесс гранулирования таблетной массы и изготовление ядра таблетки на заводе АО "Биохимик" (входит в группу компаний "Промомед"), где производится препарат от новой коронавирусной инфекции COVID-19 "Арепливир". Завод медицинским препаратов "Биохимик" основан в 1959 году для производства антибиотиков. На предприятии функционируют пять цехов, оснащенных высокотехнологичным оборудованием, специализирующимся на выпуске таблеток и капсул, мазей и гелей, растворов в ампулах. "Арепливир" зарегистрирован Минздравом РФ 23 июня 2020 года и стал вторым в России препаратом на основе действующего вещества фавипиравир, которое раньше применялось в лечении редких форм вирусных инфекций, в том числе лихорадки Эбола, а также сложных форм гриппа. Станислав Красильников/ТАСС Производство препарата от коронавируса "Арепливир" на заводе "Биохимик" в Саранске Производство препарата от коронавируса "Арепливир" на заводе "Биохимик" в Саранске Production of coronavirus drug Areplivir at Biokhimik plant in Saransk, Russia 2020 TASS, all rights reserved 2020 TASS, all rights reserved Красильников Станислав пандемия производственный производство infection pandemic medicine coronavirus machinery завод препарат facilities COVID-19 treatment industry эпидемия лекарство коронавирус medication equipment enterprise комплекс медикамент продукция disease medical care pharmaceutics C     C   v#XPN v2m%ɳ% jLj]΅;i}djryF)ol7ETlܬ?iY !j)V50?z 61o'┖H&ЕrJ a3TQE91u<;5lճd!1D J["j lE#()T+O%"UwIEVfhڤLh|[) mkgu97΃aleB8Ӂ/fB)ڦ0_ϫ?h0{qv 8|ӟG'xm/[;\OT4IF{yV*臺M'ZˍP#O??۶k3hXgGJ~SqՕZtmziCŪh^8gSzXZ<5WPʬ^@QU PJê1fJC#w_; o*Ɵ Uuc}3;{NmjXeU]5qb{/݀wk7:uwpʿͥcRb=L3*(=%QyCӏ}iM5l?6_qnէ&cU9.ϡɤV3pmy9)V3doFۆQ<-ד};8=90<&k7¢F:vC?yhÚ'wD虶.|>k=S~{Uh\ضOѣ@bG){u/,EOE6E!W.:y[Ip2K+9GVwz,.7XZa;;7Ŗy{ceneJ<K;2}nbBǩ[G8UHShw[b|]=Y89zc]hlT+iN'FM>0hnfϥoWc\yigerƱý{czPsiRͲ]'H3_\ezn'vZ"7Q.5I.?7]:G (lٲ*,,3MMN24L+cĔ#ٞ?u7Yյ$?{n.3?Qy4a: J~Ah g+So R&cETD6^3T/*my6Ry-we Mmf[λF.CQ8n.P&`lSb8jv6*s{E#;޻y6>r.W3g]NQ[K?zea)aA9/tҜ C>DϴD۰/l[&ʉLFum͇l;/C?<3&L-k>L8dmpCFHMtX4JBZwFN39Q&L-;e7;6x ZoZ.(dI,bh%O|| Q OAI%M.EECo=C˖w5KpfK5Yy (@#g -B&½x$"jX"g#(& y$|!^2p;gAzhZOvlRRU:Jz)ܫ<[#6tZh2DQ_y쀝NP(9|vt.Cr?:q *vcE1RL4zGJ33+Y!_%5f\NNg1*!mpOډ3Y \J-+SA['<B{8ͣy!Gp|Ay2ṯhA9tE+y#:<ۘ=w`ħWBxלt}84N7+{Χ"G) N0?֏f8ye'=)lqGV/mKUsO\yeݽȹL:OGc6r Թ `VVGQ]1m+նߒe؇w6;J7ȣ|7NVYJEU5RA[ʵ*~Wk'j̳W:|_Wkrp<+ZW(ds ~jdU䟘AbzbTiz+M*|{gN}MCʮ46dx8q4tu)ܫoَyWŠL/~0TՄ#:XF6QO^%^6쟦0fL(攜c`Op1mY[VmihT-L(q!gSM0`UzAs.A.xoP 8S#{%kcFYu*߂:bZCx*ŁBY"3iJOqa'|S5]fxLM@kLlmGn޿ꞩ2 q(d۝89,v"ЯWܧN|\ݫkц $^h%(bnQ#18^Ky!'DE\kX< (f8K3EYahu8tVuo:ǽfTip;FUR HEl!W1nkY0  l}>ԵT{T<:.-1?众;@?D_"LFE<߁ٿ#'bk] یƂؒJw#PdaSՌiM |nx* k3HTYKWv 5Cku^Ky't/cDļG3=IQD!BJl%Rծ 좼΂:k n_0Hkق>CCc9Ggl޹ȵڏfȳ㫢Ç p;%ueOqeN)%~Y-6N^K3Ln~yt.(=-Ux[zp >Wut7ٮښ*CFJ -z3UjZy$55bرr})"(9ݜ,D2O;uk(3(߱&!u"RG-KB3N$ט=uP t2vF?iiz撴 @D\_ Ei]/c tO/ikμ.З$j+Kd春YJΔYgm9@^ $DmV=ib;GOUY՚'bT wID^M;vv:%II;ѽmu U z^֧$biQ)z^JGQ3 K2.ӿIy 4ƼКF/$ĝ~$ƘȄ!/'O|Fڞ;nm9g*Qx#Vғۚ):w~ٟK6uf!qp>hdDv3bFi;sBKF@H ~I3']|cJm43+tZ]9쳆8֗GzpQEQEiEmHBE [+ʼ+輮ƨ)$m_c؉ͦҍґZedec|!^~ ,Bv6)F=X"2ӱ!hr7ŖYbe1wОcO,eZN0*Rb~YPɶآُ]IeUU!t=Dn7/K/E֋iEx-2611K$ŖUGrCpc$9J}芦4cv҉.+ƴDyc?lFMD1ȣ }uzonܫFKnR|lI'Z֊购Mk fԸ60lZG7#Y8g4589sCJZDU2qm6봯ߒ**58 t'|56z':xMSl?F_Te.h<-Dz;W?sqq#.q"ǣEiC^Q^D%LfI>X&b[R2bp춋uZ.\y4%_z> >u/EDpR7G&hZ:ӤF_2d'J_fH=Ǥ#2xc6|DqJFHm2=:1,RF,rRfV,Mhq7~%$Hq+G֏W/\^* d-YSxvfu][бȓ=kM1mtaɻ8PxgʹG$>'&>G+g(YqPo;7H7Erm$#t"%^ROE9b3d#4x]kc򎴌_|괋KF8fҙ)qMI"qeЌP\}k..>I[J^~hķ6G;2nF Y x=69GbjS~DUtc.ON+eOu\S%do bF)ծ<;։D^RN8Hf_tzpy-ܶ{a_і_M0StiđZxEiz";2 ѵ1llSeŊPfc} JEw 2Qq|5%R>MvoqvКЗ7fX|XJ+e[9eTƊbMMJ1nVQJN} vUwxVEIG$ɮ|YboE/{*R3ӁQkj&;$l&N܈ACZ:Ռ4 2ǎ5lWBbG#$Ǣ_F҇X,ҍ#85!q؝ ޳,VCӿ9裣qmKf,{{R-iYZYzF4t.F>~ ,kH&/v? M>&%⿈d_(O+Ū~ j6!1 "2AQ0aq#3@B$R?HբsJ9Z6B^ҫU-!jjq o<)lZ<"PkRԵ-I ZjիW;mZkM';NW MmdUUjIY@V+pqM +J ϐiN{Zo: (yڵjէS࠭^VaE[#JjRzjY&6VT-k^Vj[hdkz(GV2^-kZֵKRNDYI FҾlVYpu_jsʷ JDֵ-JXOi P+;Ͱ< <'.|>7NnR5 E- V! ZiFDSyO;/EʕdBFLG MѼ+i ScBi돲 `u>ݓk9Oq lNs8Lb.vjAjN\! Bд+JY'lP;w"A^C2h2n9j.ܩcTxl-rPGuIf:MSg(I68'G!e,M}нT-YDiPB]CeDɱ)|t!,dasɘwFXbX/̢+|e>/fIݩa|C-i.8i 6%ʂ(ojoKP9ZA.^E |b)݇ulWQLLCkPגPLu5*n/~7 ~ɤXkgGiI(xxMIۀ4njZ!I xSA1V~Ozw]LFg] ]#_#1!knܦa| >|+ïW 9^ ڔ<-JX9 ?ʻ/?D4x5U*Sb4re2TSMqò#SDVEdBEBD}қ~}Nu.i ԋWBdϺ;-!ܢ[SNxňMt ,>YO6} &^"q]_lbuq0T]#0y&ȄXנA(p#Fia4T03PR⥯a d@}(4]atK!0kX>!~25 S"f@x_Sca{.$8A1 Ab\ E`%8kިH߲p"|W; !ەґj!6K3ɾ"4!M#Z*9ahfgdq0&J)MB_Hi/lXC|FhIr6 {WX|P#T__HS` k(hl`-L]JL#(%Q?ccOt55nr;yci TRx)kv6& ůU^,TOhxikCL"Na4G;,wKt'SvP2 C|6-; c n<:pnPwPzXBjI4?IWͩ&+ak I}\dDPK]xјaQ0H2W黐2RZ۱s*z)dјmA4躕J \pЁ6NgM姕 PԫMlU^}= Ishf FIxw,<=sr PS6FlM&:XDLe|6gi^P{}ӥ`XuKJv?u#= 돟s%e(fӠ3Mo9bHM~ly*A0N\FnLzֵ-KQ@6t26*"V#) Q|=pTF<,eH<u=j u*{g+V3C,,Z60PT=TIV s4n8AɮV>+/DFC#*գMOmd,G9M)vl'o;FhQȬFi-LΦĴ4rS0kjOu7qTRV`Sub;MiTekԬѸm=i@`i QG>" :l#t7jЙ4)}š;6ydrS)i`~׾MEF{'op Qp[wP͎7 Ej,;6*bZ vi]2:4Z XkJpmOSjl_Ë:X=gעK9.0fH8Ud>G5#VZV|XKnubtv[&MENX08]p26rhY>QgIIUM4h%6_LyI6#O!kUgiZnKUF^ܲ\>e6(:˕[5`'_& JLH=L<-]a F}IUީZL-¿ff՟fEjXsXX.+iQXBT634q:&%2M 2twgCr}wZx[,-eiِZ-1ےۄj(۟E|VUeي2Y՟e@J݆Gxg 8bsA~=?PVUVjܯ\՘,B.k,fΨg\X^Seg6+-*I!+4=>a^9~(<]VBKUWEk_ [qvmّoZ,96 uKw+wP.(E2 rՉ@~Xf/\w10HV6;b5 Q|tZ 8@B:} f_{~\n`pXGhZ/ Dckq'=pC&iF]ah[3Wp]Onj2=QٲaPI_N7x K,ppXcOs7[)6{Y/Ye&-K'ROc'Dpx#+Ub:#Y2gP{tZzV!TGRԞ oXErc)>j,o* thKcy[F9ArQ5wOV4Ϳ[M;蛜ϰ=edMxP& 4ZNBmfViF=Tfk/G4&'|n;2=zQ#ޥ3l,+gdm vDf.O$6<~nf.-]FVQYt4{/Y" #1d2\;m'|UMd \sRR N|R %ew6]ڛ'VJ6bt9=kVr};|C_2{X|V<0ݲ @+d=nfLH:V!;?B&m> C {nm[)F$>M]?0:9\eA"6?i]apVkˁ)h6j~jz-Nf+xn5]ҧk:?k74GdK'wqZWn(lp: F3РsqFu 6ݍWW8]d\lZ|=V4oj,bfE^% eYe}`ݻ E7A,pqhp2 k>WF 빣#m6Of6wq j#c^5E*G?m-wHJHw51\WIڕv䰹?klP 8)6WH+^ȧxs'EFdY_[x,Q9iGrLؾ{؂WTDp@{5̓jgM,]89d;`IVz;8G$p)[ KP3(h~QZ GhF0b勆WDH>˅v`uw9]>j08Śfk+Uu"֓O4sX[~`l>m]Ltr8ϗ5* 31>j7q j2~ ,qwcg1`+qEn/iڮah̓5g7Nu 4~lWIFKj0mz|UT/̘^H\5c*hOlOD;SN5Oeh-M+g1MxX{}D)nkPf:)(o]{p6&3+_TppJ64x]U&_,Q?^<XXu[ScUVV[>|_C6ʩ<?T6q[X6>?f?ҟ v:Z~B*p4h6ChPq=`9[ % jjq?J浃Uݾ v.:-/mSœ&_}SJF+{=4?EZUXwc*dڦ\r`R99K[O+l-5xH*ERNl_~ZE4MnZ p_L|AZğmwClkfD4-6=jn=n,6X{PM5v  ,B3U'5"V[-k.给MV6xnj5g79* m&ixdu10u"T噟` -F2@f̈ij߻1%K-Z*ݜ _-a&KZ}q˗Vͼ)YVdmIn BhT>QI]o:&)*_Ϩ_t^ ~/]X@o=7:h S8>jY IW]g*$l'ّuuQl9x^pr\ V&<6'p Y!8#F?j՗edi~E3dԇ^}I*,\6uy&l/hatܹ_@^K_|DǓ;_b8gUGoV*HY!69Cf?`>,ddcJ}%dAxQ8H->(;Nd4ndCF!gyXt\=*݁9Mk:BX(W( ڞ!brZ\bsYvGDWM7\eylq;\bkQٔ\@ɻoLy5%,R9=W.GٷwǪ0lOg;K cl4bst[b?OUMC7ǙWT@Yu#xgϜoc9rR>>SjL@YvMOGV[8yw;,7Vr;ce3=l}P{:+S&J[ۭwp^)1GVhW3n|g5m20dЭΈ=ȩvS.rnN=V&ޥjʁbl}4+_!<X*+ dI칮Ƕ`irWsI'k3Z8{ajE>K:)c4?UeC|'E.VK2 Hz  H통ߝT a䣤 vxw5L,pSNύMlY,Κ!&8%OO}5KwsFm$dh+I4:T0JC}ep\K@Vy'`pݐAݒĖHgx+ xgV 4]GU1\}JFs$>&l(I \Y~ء`Ӷo6%fފ:XvG?\C>[zrZ+UfVb 4lGry7myIj-G'S #H:(ɳ-+{ ߳7/5N-ƈr VkIu#wa1Bҭ#"m>l-:1k~^abb>+.%}rȬʽejQroK,zv;3ՓB{sjk #oB3 JV f>jLju@Dhq%^[ojO5ºYjXerT2s}8JepjYj+ĬVHI?"Ӛ޸=+,]VdZU˗jV#%=kf4.#"=i;%g^%ݘv=az^HK_Tn/p N ZX^$Bswf[۳'!1AQaq ?!Is'E-j5L5QVHLQWyqD*l(ALa fi"ˋHX4? UW#Aoc)؏D,Mqˬᅃ4/0<`ab>6Al2,U!k,m/t01WQ1:+92XP8p2\p4Mc{YMX5`pQ+._;$ppd ԼQ1 DKy[jR[;ax=y@8* t5" \*džvFi(XxiGE; PwD8Mר}_KNe}p*>ԷP1%Q? Dq ٯL^glSy;Ah2~҈myS*"NAVrFQ5=4]cS ŜⅷLmM(:l--rE1Ux* KG,^siR.U q~=83b6d}9;Irhq#"NoĮQ Sk3媛Rfq 8kǶo!e}+2ay*4x%]a=̭ҵ9?PD~.;ygqCScW0DQm̬{#[1oeq$vat'}&eaӸ&߹K 0{ª1g' CAӼ]L;C LG8( n{R~$̬p: qG`I=;in3a'CqS2l%Wo);GFxHw26!/.Wc#@*>X#W]"| o>NHz}5B=!'pH9jF-2_H32Jܭs xV6ʝe֤ ܦJg(=Nls^+EݫN=ޱ eo4=t~`_Ђ_^^KٻA5]q5,m vF#]ɧ*9iF/¸-b{n] (pdWo$Ȱ@%x*d " -J-/p@i^$%r}ũQrFp瘑}&%D@p!\E8|\b?0} p#E3Q… ?Su 8" jY$3_e#x}K<2q Pڋ;nS+Í(&fЈn䫩+VOR2vx*Ћ 5yˈE7:_ Ž۹QEk6)ۋotmZܺ`@m}mf5rJq#u=4z9J앷 Vck2PG-Ph> ch!CZGpA { PFMK:vY; dLJM Cayux@p{Qpּ}Ò(:c`PnmbDa5,H>nߡA˔F|Udp5 l}}zGQl?;zu`q>X "gZۏJ+w73ݤ(Yxk4k]/bK\8hTKl$~`~Yp2{H# 1♙Dsu|d!]KgKCTN\ bGjg,fuT4&W/Vb, 5G@WZ8a EcXGB'㧴l?5Lwb.~/Dߢ>b 90Vwu.bۇgO&8O0AlmV9HU]?&}&ry#(S^4Qjb rAη ii ff1&p񹎋p~LEJ wTw`6ScqǾ%(yn݌E[HtKq vϦں&@'u8'O={4Oىf1y, #kD1@4ԣ.|Ǧ+p]ao+9Rd}.7Fk (¨̿I 0vļvJ$9̶^Jnڂ&e1`ˁzLuwԶedfQYKEE{+דjs !ڗVx_Ib}5^%aKlrhDw })s&϶:6NK9Q#m)752ǞP ~+*"ɰp(3qf!:h_3k &xFUJ:G[q7d@D|DԬn! Uݑ W 'L׾˺9"@_LJ2cCᠳrw ր.LJ_qe+4+?._#;.SNRM8-X^Ο1Wf-[6 &2j+9R{rFQC5%e*;);9Qn@n JT /CL?C=ˋ($) Ki~ sFT( X'[fr%ap 80eN\~gKu7Qe$';J밉8L]u w5hc͕j,2exn퓹Yp K΄-Yr8$,8|2Q~Gr}B;$t[v\hy ^WLvE̼@51Qi>_=JM  LteAM]oNL"4v'_̱>#/Gg4hi¿,P ~#TfQ6*d!} CaA\q) %lߊ`8o[GA9MrԮfX˭^8k;[QGfL3K<"^jW}8W'؍Tj6 鏝{RoKu-SG<`J'>R~5˃RLTβZ B#3 bS/K2vb! tL7ABi[1…jgKm:"vKX~FƤx.٥Ayy&*V f)YC9vNsRڥUl`0uH2FntZS4)8䇯 C .wVa57ςJS(2BَuVO |R3e$"|soi E"MuCq^\ iYz) b58Ŧ7bX2RN+C/+ŋqƒF ]ɔ=Wh!1¿Z4d25JuzC7߅6* AӚHF1Vf5g0["\%3"\L%\ {FraRL"f\p263KZP|H{xP$JgQe8XL+֫D2 Wj 7Wnb+rľ=&)lp3.aE Kg;PM ^1)~ƞpӭV'D*!ɛYd)=czv/{7թL_ .匓 WWI: wϡط\h+ٶіEF ˸my+O,@&cA:\-PGshQk;Hhoq84p8i/dvz2a XE~"=,Nsc'[<ߊE2O&K8&vPTz!GdN~evR'zSL%\ͻETw< IID$s{{I; zx;Cy®ݺ\Hv u )<2@tOڱ/(z& j[%FD:iĩ.ެ'!1AQ aq0?\|ibٗ$|Nv^!bǂFSy^}bE=1qKorO&m].zY7geDӻ^I1[scb:@K~c˜r ۇzX$lG(eèB Yq&$$}e3 sgas..0@efpG>,`ɞIܴ~#n寕x\˖"o/6Y 66~1H\:'}!G^"8!Y՛Ủa'6|!i,Ň]9>-ˤ&s.,Yk/rb$ZGvqk28`|1 I&Op_q"] RC`l%فY3r:|?{9iw,ܻFx99!6; xzbeic9+ex6%c+D;0Ke嶐L8 N1`/3 R W`Bq#bEɌmqjTv,xI%7{31PV6;̇iݽpi)>2]904.\]%;]~ G8Ͽ>6eœّښJo ?}Ci8FPq |#b6b'fԍ㔲'9.J9<X݇̾Br$aHWʰ7]vYN&r0yy<xG :y3HDv9 FA$Lq= d _~d,gvY߽ۻO2q n1Ƽ_C_4n.+w)Eϻܿ#HNB_/ơyׯq?KWoI q px}}Sϸ`2lp=ǪΒA5Gmzzt< z&߲s!MIРׯ%n]H?:Hr\W~[F V;.zeVhmG:\K[.ي4:]x22iˍR!cp;tY ]G+%T<ݡv^eq6f:i8EϿ$(W>Zyp¼ܳ^D/vxcdl+jOfnjhV[& .̝.ο~7njspz(!n,<݇{!D:oPt!o&h9Hemżφz6iߍp͒fJ ROt5 4"#KԎYCq`~$ϴHtN_H7a'sI :ig&*FxF{ fn&g^#&3`ٜKZno;̘G*XOl2&,tpB^'$_5!11ŌpN9rsn\KYcrr{%gqn Gu~|˒K+pl.K#ΰJ-%%p}[i=eo(!1AQaq 0?%MQj $qAB_Z0FGZGP4ͅ~1ҙQ*q)z hi\]=_Kleq.UA0Ő\@ >_BAQ^^ IfĿqXZeЊ1=$"3f w-`^+=]KzT*BగEZwh6a'tÃKB(Q0`Է `A%ATB&9K /5̡Dw"s=AG|lX-B^**"i8McYA@eb[ q(®HS%j0h!u&e2XN`_,.b3,QKI;,ee3([@%,H٩@;N`Hũ| ejl5wu9)#Fc@ bef6/ Gm\yyh7*cj[OFt2DTKf]:aS^$ U+SvLRTD[ԵK3 $, iE;h* Q.WXaLHԘ&D uE!e j ˹C[Kw0C.\x+QyZ*]nB5_yJCn?f/wrlsH1QZqMW=χ+Gv­7k-T*'.!/-=,>[GPEe0L \yCoiWE1\\a4Na~hDŽ)2TeQ-/Iן]-{4b6ad{8 koЮeSC5E#qs+/*f\Ȗ!fY CR3I҉dWݎhG@ ~AXoe=ㇼ9>UszT/S mo7|q!.)P ,cko|thaُic^lܩ&?d A0]rs.JlΏ  K_>؍urrzw? 5hu2;%rh:*|@AJCTL) Y՘[^d|Bk3 d&\KqrOY/WQ4p}* y lkAJ/We)y뷴Tgyk׷&!΍hyUdV;B_*lhi-o0uDA} R#Q0}j>5"1'3!Wyg8<_2b!X0(x{pz`L`_>-ek#b=ÔPm8%DE"SqJMahDzJLl%Z`u4OW`Z5Ġ>.)^iQˡJx- B+BA?%BZ}<@q"x錨P;mr2~ PLKp^Py%;psu_'4"o9s s~[WEgmmz+K /z,oLc|?BPQnw(X&U+7҈KH7Tv.kp̟i^c8F(d.~"a:Q=^N4@wr\ɟFfqW~.ci&Ʀ P"!.[00hp hr!2΂hqG,,hnͧ.Dwf`€l@Be[d5/Wv;q)0S7NԨGGׇrt wZfb3c,)b[:V_fL,̱Oz >GVh}>epz/ n;zDhbiezgĠw1)q|1lSI̥>n EgX >Tm ."DC,M/R0RN,6= €x{J\zD4P w3oYﶭ{\S)r_ipEz"FkM*?2lRNXF>fh7(bʸ iB\)S'?P7cˌ(&D<%Tl9J0v Ɗ)8QJb(m=ȳ2Z!Ҍ @ z ]Y^rBB'0 &]CqR!"̐.*~ʲj.VzL0T#]9M=3e s%tR"[KeQ.m76?Z'x FA*Td3TDfJaGq䚃q."/0r3L$w JL\PӹnCh)(:)Q+6?Y }$Ju $L dw0J4m~6UK`CTXEdWC%Fb]b_Kq%ts&!1AQaq?Q# "_ ?A^ʕ?#$Ee#-fR/2Q5  1ȟr ~F^N_ɕTpq;C8 D)9#Lרz;uSeyLX"N iX/ qPֈ""eT^1.m(ep< f2KDl:8VJabME%\?`{@51Cr4L1@| n4ns|3"$*1Ywjľ9@ HU$&$ 3opIFZyJq6Я `6|7&|K eR`s}]?Lxˊj ]5P@0/F&&p|lw<{) -!v ]^-ѨER*~HTht0JlĨ&kjSNM ^(HkG"@)csʆR8@-/nY_KR*nsPLo5+O.(Yo쀗Eyʛ:L^P0RhLV<\gSc+ESOd_n$]*7^Ѷ+WF0Tk(4QnCĸQXxaj>@YUш g;&.5Ph8DlN j̸;cju9;eK#ހUwh~c A3er. !Q*oOL+TjRQ9A+O%.Fjխz܁ey/5Vlan ^ZqZ(4R^Ql1pYfuy P O7% yxS Wr 閆-PLaU!0Aʌ0PʼnD,spUFx.@4& _eij\-ģ&<aj}N8<^]WqY!H,~ځs _V#?Pٲ/#BޣagyPdsM+Ah-jk֓c6FK(g]Gf/5Pq Dq ? C(?%kc$l-]eZ&Ҡy@u3&j6!l&RLGT- a{q=E y j(8URFTf7YeCGrq6Xfːa."AT0Y`fW%Ve "*x0l0Dl6A\ğ9{#+hF4$ +S:k qgq@1]=MN":]Mbm Fi-p*&Fa3h=$j[aYc a[42̒!v4# AZ;6U)[J3uG+eʨ!\$ĺfs/T Jz+<B:@(̵?#P04`W<9ݷ*א)r+ph6L DL*!ȑPXƱʯoI|ypRѾ~ |qi35YN弃'žUt[ `N7la.) uÿciC4sdhYC(.\ 2m(K?='Z+isB:RmAh@{9eD΢fڲ48':U;,63@^+Ů V5@Ʌt3y蠱;Lȫ\HXL7qUi&pz u:xq)j%s Y 5wFxcs" fMtapc cc֎>`nAqR4c*bܴ+@l~F"N(f;3O3yT"̥XX#^NXnU\ЕL34y;ʷQMXy9CPPWU+.mdXW#0|06aGpPwU/ƧSg,TL8ZZyFPFwC$Y Y|h[@ cͻ“tEQCP+mQeL6Zb V/D6IU F_T/8VbM.dY.NU䉔\p- "U?{w+69UDZ$b6m^A\_u.V8q9f-??3 K98PJ d/Ţ<*e B̯֜s9y0g`L\)IܻkQ,RPw; SE8#@(PPm`9o9* b&,R̂DC݊Woo9 &ELX׀CcVb"kn  KPQmMu {"ro+t~eﭩ`V< ѱ"-nWZl)j }_EGU /~[o&&̤`iW cPBjRX Gt9!d1'6f+S&5 'H Qvq\CB6 at@^K=%4" P'uU|UMjցq7TXݸŬ [YPrjij$4_yG*>X\>aLۆ}I̻PB)-N5Y~CLbcA@#@t/L&Yehr(*\E .ƍ\yQU>l|=eQ*{ aK'MKh#0n_D.lt 3N:_zi . p!B›0sjn]Y|i"4SIF!L˓TdЫ)B!AjrmbRZAu(ő|\]}&ZD㔙bK@BપKE+ Y6-#Y&qZ[Arlt \AojeE)w}wF$|g2ohh0tQ ,"U*L0"Դ %#UMeZPO#$cF2K)I~\Ծ86H *YX0ٝt[Wh]Dd t4!X%AF"5bX(`&Z ;,,fPrPToC-A+˕-(XI⚞kҿ~$eBeEX'p-H,( 2 "O b%M7L7w|y5TU<).69X ُ'*&Y͍W6ʎ&QȍЬt}.{*X0[VHAxs 6"X!i0 4;{z"EP0b(x`Sl9GU!ؓ1`KLpêϘHݿ\lV_YL9gD㢽q V[^8e2^KY̤jn)LL[$#U0R`CTm@̚K3:]SgdXpR2MPՍf5U2ˣAV/nV&orrL0K{loLZe)ҟ@.򭊕(ājT .Dn9;+ª = qE}{~!̀!p K`IiԢ\U3&Ѱ* SAd mEWEh:"nF#jkc IF0_Ww^C*2#ߞ&%V=zs1DܭVz w9̳,@wr-W3)evQ@~ʦXWY sXM/>+xf: Z iw2,ˊBXv3gp!Z+ o0 6 Z@,wa%uhba(=fPcX DF*[= Ro݀v1{j5 B8&syМ#32bTTbwV@%JͯhQ"Q5n()GuHYLld{ Ukh#邀HrAP_Xn"lPkK6Yaɗ85x{d:o쀂XU)?@馡cPt}#Vio1B gR5*07‹#IPڎ)eXtܶ8;QKs _id-h"GJZ5(]m Hq0;O0`A v.k—|N>0lY!1M^N5+ _BEօSݜrZ,~{HatI:a 17 C)l%9\u%^'&62H%@FˍbǁJD,UA湄f'^%!Cs_4`07siuČaC/s [{zһ]X;-I`^cz6 00B`rѲ0f2Y'#1""PPqY-s\d.\"4 }Ux`M>Z[`ԇ@< 69CQK9ag8x`a !AWL# j\O5aviBkɡR"xLbNsRB1eΥ(̱"tQS+O ]ʖ,Eۈ W ˾)|$TBt Hx_FXBš.dȊ""V,~QvE"qH\p2wzճxሱ?